Your browser is no longer supported. Please, upgrade your browser.
Settings
JAZZ Jazz Pharmaceuticals Public Limited Company daily Stock Chart
JAZZ [NASD]
Jazz Pharmaceuticals Public Limited Company
Index- P/E22.58 EPS (ttm)5.04 Insider Own2.70% Shs Outstand61.50M Perf Week-6.56%
Market Cap7.00B Forward P/E9.96 EPS next Y11.43 Insider Trans-5.39% Shs Float59.85M Perf Month-7.44%
Income328.40M PEG1.29 EPS next Q2.60 Inst Own95.00% Short Float2.66% Perf Quarter-16.18%
Sales1.31B P/S5.33 EPS this Y-73.50% Inst Trans0.27% Short Ratio2.61 Perf Half Y-38.92%
Book/sh25.45 P/B4.47 EPS next Y19.93% ROA9.80% Target Price182.43 Perf Year-30.11%
Cash/sh16.24 P/C7.01 EPS next 5Y17.50% ROE23.10% 52W Range108.50 - 194.73 Perf YTD-19.05%
Dividend- P/FCF14.03 EPS past 5Y43.30% ROI3.70% 52W High-41.57% Beta0.67
Dividend %- Quick Ratio3.80 Sales past 5Y55.60% Gross Margin91.80% 52W Low4.87% ATR6.79
Employees870 Current Ratio3.90 Sales Q/Q11.20% Oper. Margin39.20% RSI (14)36.59 Volatility7.62% 5.68%
OptionableYes Debt/Eq0.82 EPS Q/Q239.00% Profit Margin25.00% Rel Volume0.97 Prev Close112.72
ShortableYes LT Debt/Eq0.75 EarningsFeb 24 AMC Payout0.00% Avg Volume609.01K Price113.78
Recom1.90 SMA20-8.54% SMA50-14.33% SMA200-27.24% Volume592,017 Change0.94%
Nov-25-15Initiated Bernstein Mkt Perform
Nov-10-15Downgrade Mizuho Buy → Neutral $164 → $140
Oct-14-15Initiated Northland Capital Outperform $200
Oct-09-15Initiated Mizuho Buy
Jun-29-15Reiterated UBS Buy $190 → $210
May-26-15Reiterated Guggenheim Buy $210 → $220
Feb-25-15Reiterated Deutsche Bank Buy $176 → $185
Feb-20-15Initiated BMO Capital Markets Outperform $200
Nov-05-14Upgrade R. F. Lafferty Neutral → Buy $200
May-09-14Reiterated R. F. Lafferty Neutral $140 → $130
Apr-17-14Initiated Canaccord Genuity Buy $163
Mar-07-14Resumed Barclays Overweight $200
Feb-26-14Reiterated Stifel Buy $145 → $195
Jan-14-14Reiterated UBS Buy $130 → $164
Jan-14-14Downgrade R. F. Lafferty Buy → Neutral $140
Dec-06-13Reiterated UBS Buy $110 → $130
Nov-25-13Reiterated FBR Capital Outperform $105 → $198
Nov-25-13Reiterated Barclays Overweight $112 → $130
Nov-13-13Reiterated R. F. Lafferty Buy $102 → $118
Oct-30-13Initiated FBR Capital Outperform $105
Feb-09-16 04:05PM  Jazz Pharmaceuticals to Report 2015 Fourth Quarter and Full Year Financial Results on February 23, 2016 PR Newswire
Feb-08-16 06:37PM  Former Leaders Show Up On New Low List; D.R. Horton Sinks Again -6.25%
Feb-05-16 01:06PM  How to Play the Biotech Selloff at Barrons.com
Feb-02-16 04:40PM  Jazz's Phase III Data on Defibrotide Published in ASH Journal
09:04AM  Ignore Regeneron Pharmaceuticals, Inc: Here Are 3 Better Buys Right Now at Motley Fool
Feb-01-16 09:05AM  Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD PR Newswire
Jan-27-16 01:30PM  One Stock You Need To Buy Now
Jan-21-16 04:33PM  Use Composite Rating To Help Narrow Stock Field at Investor's Business Daily
Jan-20-16 01:53PM  Over 1,000 Stocks On The NYSE Just Hit 52-Week Lows +6.57%
Jan-15-16 06:00PM  Walgreens, CVS, Illumina, Jazz Top New Insider Trades at Investor's Business Daily
Jan-14-16 04:53PM  3 Stocks To Watch In Thursday's After-Hours Session
Jan-12-16 04:20PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and +5.16%
Jan-08-16 07:20AM  4 Pharmaceutical Stocks With Big Catalysts Pending in 2016 at 24/7 Wall St.
Jan-04-16 04:05PM  Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 11 PR Newswire
Jan-01-16 08:08AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : January 1, 2016
Dec-31-15 01:59PM  Drug Makers: Valeant's M&A Prospects in 2016 at Barrons.com
Dec-14-15 08:45AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : December 14, 2015
Dec-08-15 01:17PM  JAZZ PHARMACEUTICALS PLC Financials
Dec-04-15 01:43PM  Hedge Funds Like These Five Declining Stocks in Q4 at Insider Monkey
Dec-03-15 06:11PM  U.S.-Traded Eurozone Stocks React Mildly To ECB Vote at Investor's Business Daily
Dec-02-15 10:56AM  Here is What Hedge Funds Think About Michael Kors Holdings Ltd (KORS) at Insider Monkey
Nov-30-15 08:03PM  Smart Money is Flowing Into Jazz Pharmaceuticals plc (JAZZ) at Insider Monkey
07:03AM  3 Companies That Could Become Tax Inversion Targets at Motley Fool
Nov-29-15 03:08AM  Should You Avoid InterContinental Hotels Group PLC (ADR) (IHG)? at Insider Monkey
Nov-26-15 04:35AM  F5 Networks, Inc. (FFIV): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-25-15 05:33PM  Don't Forget Hot Sectors When Looking For New Stocks at Investor's Business Daily
Nov-16-15 01:43PM  These Biotech Stocks May Start Paying Dividends in 2016 at Motley Fool
Nov-15-15 08:11AM  3 Great Stocks on Sale at Motley Fool
Nov-11-15 09:30AM  Jazz's Q3 Earnings & Revenues Grow Y/Y; Trims 2015 Outlook
Nov-10-15 01:34PM  3 Midsize Drug Stocks Moving On Q3 Reports at Investor's Business Daily
Nov-09-15 07:09PM  Jazz misses Street 3Q forecasts
05:43PM  After-hours buzz: Gap, Rackspace, Caesars & more at CNBC
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today
04:21PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:18PM  Jazz Pharmaceuticals (JAZZ) Stock Falls in After-Hours Trading on Earnings Miss at TheStreet
04:05PM  Jazz Pharmaceuticals Announces Third Quarter 2015 Financial Results PR Newswire
07:07AM  Q3 2015 Jazz Pharmaceuticals PLC Earnings Release - After Market Close
Nov-05-15 03:00PM  2 Hot Upcoming Healthcare Earnings Calls
Nov-04-15 04:05PM  Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences PR Newswire
Nov-02-15 07:34AM  3 Stocks to Buy Now in Biotech at Motley Fool
Oct-30-15 03:07PM  Shire Helped IBBs Top 10 Large-Cap Pharma Stocks Outperform XLV
Oct-28-15 01:53PM  Jazz Pharmaceuticals Plc Value Analysis (NASDAQ:JAZZ) : October 28, 2015
Oct-26-15 04:05PM  Jazz Pharmaceuticals to Report 2015 Third Quarter Financial Results on November 9, 2015 PR Newswire
09:02AM  Super Stock Case Study - IBD Investing Show Excerpt
Oct-24-15 01:02PM  Better Buy Now: Medivation Inc vs Jazz Pharmaceuticals at Motley Fool
12:44PM  Amazon, Alphabet/Google, Microsoft Earnings Beats - IBD Investing Show
Oct-23-15 09:08AM  ALNY and JAZZ Hindered the Top 10 Mid-Cap Stocks on October 21 +5.11%
Oct-18-15 08:51AM  5 Trade Ideas for Monday: CononcoPhillips, Discover, Electronic Arts, Jazz and Packaging Corp.
Oct-14-15 07:08PM  3 Value Stocks Near 52-Week Lows Worth Buying at Motley Fool
09:36AM  Northland Starts Jazz Pharma, Mallinckrodt, Shire With Outperform Ratings
Oct-10-15 03:26AM  Jazz Pharmaceuticals Is Cheap at Barrons.com
Oct-09-15 04:23PM  Tesla Downgraded On Model X; Jazz, Allergan Get Buys at Investor's Business Daily
11:25AM  How To Invest During Biotech's Latest Crisis
Oct-07-15 04:09PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement
Oct-05-15 03:06PM  Don't Worry Spec. Pharma Investors, Drug Pricing Legislation Probably Won't Affect You
Oct-01-15 10:20AM  Jazz's Defibrotide under FDA Priority Review, Shares Up
Sep-30-15 08:30AM  Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease PR Newswire +6.41%
Sep-29-15 12:09PM  How Did the Top 5 Mid Caps in IBBs Pharma Sector Perform?
08:42AM  Jazz Pharmaceuticals (JAZZ) Crumbles: Stock Falls by 7.7%
Sep-28-15 02:36PM  Turing isn't alone in overnight drug price hikes at CNBC -7.65%
Sep-25-15 08:34AM  3 Mid-Cap Biotechs We're Excited About at Motley Fool -5.83%
Sep-04-15 08:50AM  Should You Get Rid of Jazz Pharmaceuticals (JAZZ) Now?
Sep-02-15 02:26PM  Biogen Wins Round In Patent Fight Vs. Kyle Bass at Investor's Business Daily
Aug-25-15 09:30AM  Alcobra, Jazz Pharmaceuticals, Nippon Telecom and Toyota Motor highlighted as Zacks Bull and Bear of the Day
09:01AM  Bear of the Day: Jazz Pharma (JAZZ)
Aug-21-15 01:15PM  Why Medivation is a Stunning Biotech Opportunity -6.26%
Aug-19-15 08:53AM  Jazz Pharmaceuticals Plc Earnings Analysis: By the Numbers Q2*, 2015
Aug-11-15 08:33AM  This Undervalued Biotech Company Just Filed For FDA Approval and No One Noticed
Aug-10-15 09:22AM  A Victory For Free Speech And Common Sense at Forbes
Aug-06-15 03:12PM  Jazz Pharmaceuticals Misses on Q2 Earnings, Affirms View - Analyst Blog
04:27AM  Edited Transcript of JAZZ earnings conference call or presentation 5-Aug-15 8:30pm GMT
Aug-05-15 06:22PM  Jazz Pharma Q2 Earnings Meet Views, Revenue Light at Investor's Business Daily
06:06PM  Jazz Pharmaceuticals Beats on Earnings, Misses on Revenues - Stocks in the News
05:39PM  Jazz meets 2Q profit forecasts
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today
04:13PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Jazz Pharmaceuticals Announces Second Quarter 2015 Financial Results PR Newswire
03:27PM  Tesla, Fitbit Top 4 Key Earnings Late Wed. at Investor's Business Daily
07:07AM  Q2 2015 Jazz Pharmaceuticals PLC Earnings Release - After Market Close
Aug-03-15 06:21PM  More Pharma Buyouts Ahead? 3 Top Stocks In Buy Range at Investor's Business Daily
02:18PM  Health, Consumer ETFs Holding IBD 50 Stocks Set To Report at Investor's Business Daily
01:05PM  5 Top Medical Stocks Reporting Earnings This Week at Investor's Business Daily
11:06AM  Pharma Stocks Show a Positive Trend
Aug-01-15 08:02AM  IBD 50: 10 Top Stocks Reporting Earnings This Week at Investor's Business Daily
Jul-31-15 10:56AM  Jazz Pharma Could Be Worth Over $200 If Xyrem Adds Long-Term Value: Here's How
Jul-30-15 06:23PM  Six International Leaders Preparing To Report Results at Investor's Business Daily
12:32PM  Will Q2 Earnings Wake Up Jazz Pharma's Stock? at Investor's Business Daily
11:19AM  Will Jazz Pharma's Stock Awake With Q2 Earnings?
Jul-29-15 01:02PM  This Winning Biotech Stock Looks Like a Buy at Motley Fool
09:00AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events
Jul-28-15 04:03PM  Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up at Investor's Business Daily
Jul-22-15 04:05PM  Jazz Pharmaceuticals to Report 2015 Second Quarter Financial Results on August 5, 2015 PR Newswire
Jul-09-15 08:56AM  Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz
Jul-08-15 02:04PM  Rate Hikes Won't Kill Pharma M&A Boomand These Stocks Could Be Next at Barrons.com
Jul-06-15 03:05PM  Are Patent Challenges Paying Off For Kyle Bass?
Jul-01-15 04:05PM  Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 PR Newswire
Jun-29-15 03:53PM  Why Jazz Pharmaceuticals Is Winning
11:11AM  Jazz Pharma Still Loved At UBS, Firm Hikes Price Target To $210
Jun-19-15 03:34PM  Jazz Financing I Ltd. -- Moody's assigns Ba2 to Jazz's new senior secured bank facilities; stable outlook at Moody's
Jun-18-15 04:03PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material De
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate that is in phase I clinical trail for use in patients with narcolepsy. In addition, it develops products in the areas of hematology and oncology, such as JZP-416, which has completed phase I clinical trial for the treatment of patients with ALL who are hypersensitive to E. coli-derived asparaginase; and Leukotac, an anti-CD25 monoclonal antibody that is in phase III clinical trials for the treatment of steroid-refractory acute graft vs. host disease. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COZADD BRUCE CChairman & CEOFeb 09Sale111.372,500278,425281,896Feb 11 05:01 PM
MILLER MICHAEL PATRICKSVP, US CommercialJan 15Sale122.6610012,26613,561Jan 21 11:43 AM
COZADD BRUCE CChairman & CEOJan 12Sale123.812,500309,525284,396Jan 14 06:52 PM
ENRIGHT PATRICK GDirectorJan 05Sale138.0910,0001,380,8904,519Jan 07 04:46 PM
MILLER MICHAEL PATRICKSVP, US CommercialDec 15Sale136.9910013,69913,661Dec 17 04:11 PM
ENRIGHT PATRICK GDirectorDec 02Sale148.4942462,9601,310Dec 03 04:29 PM
ENRIGHT PATRICK GDirectorDec 01Sale146.5910,0001,465,9104,716Dec 03 04:29 PM
Mulligan SeamusDirectorNov 23Sale147.9010,2431,514,9281,130,547Nov 24 06:50 PM
Mulligan SeamusDirectorNov 20Sale144.6817,7252,564,3681,140,790Nov 24 06:50 PM
MILLER MICHAEL PATRICKSVP, US CommercialNov 16Sale134.0310013,40313,690Nov 17 08:47 PM
McGill IainSVP, Europe & Rest of WorldNov 13Sale135.672,821382,73719,146Nov 17 05:24 PM
COZADD BRUCE CChairman & CEONov 10Sale128.532,500321,325289,355Nov 12 07:19 PM
ENRIGHT PATRICK GDirectorNov 10Sale135.2910,0001,352,8624,912Nov 12 04:25 PM
COZADD BRUCE CChairman and CEOOct 13Sale131.502,500328,750291,855Oct 15 04:04 PM
ENRIGHT PATRICK GDirectorOct 05Sale133.7910,0001,337,8605,108Oct 07 04:13 PM
MILLER MICHAEL PATRICKSVP, US CommercialSep 25Sale145.2310014,52313,890Sep 29 06:56 PM
COZADD BRUCE CChairman and CEOSep 08Sale163.072,500407,679294,355Sep 09 07:14 PM
ENRIGHT PATRICK GDirectorSep 01Sale165.9910,0001,659,8525,304Sep 03 04:03 PM
ENRIGHT PATRICK GDirectorAug 27Sale167.8742571,3451,734Aug 31 04:06 PM
COZADD BRUCE CChairman and CEOAug 11Sale177.822,500444,550296,855Aug 12 05:35 PM
Hooper Suzanne SawochkaEVP and General CounselAug 11Sale177.824,000711,28037,855Aug 12 05:33 PM
Cox Russell J.EVP & Chief Commercial OfficerAug 11Sale177.8250088,91058,602Aug 12 05:31 PM
Treacy PaulSVP, Technical OperationsAug 11Sale177.821,330236,49411,401Aug 11 05:54 PM
Sohn Catherine A.DirectorAug 11Sale177.82654116,2935,384Aug 11 05:44 PM
Winningham Rick EDirectorAug 10Sale180.00801144,17814,659Aug 11 05:46 PM
Sohn Catherine A.DirectorAug 10Sale180.00801144,1806,038Aug 11 05:44 PM
RIEDEL NORBERT GDirectorAug 10Sale180.00801144,1784,865Aug 11 05:41 PM
McSharry Heather AnnDirectorAug 10Sale179.99867156,0526,093Aug 11 05:37 PM
Gray PeterDirectorAug 10Sale180.00867156,0595,389Aug 11 05:35 PM
ENRIGHT PATRICK GDirectorAug 10Sale182.0210,0001,820,1775,500Aug 11 05:34 PM
ENRIGHT PATRICK GDirectorAug 10Sale180.00801144,1782,159Aug 11 05:34 PM
BERNS PAUL LDirectorAug 10Sale180.00801144,1785,589Aug 11 05:32 PM
Hooper Suzanne SawochkaEVP & General CounselJul 14Option Exercise46.834,000187,32050,420Jul 16 05:47 PM
Hooper Suzanne SawochkaEVP & General CounselJul 14Sale177.794,000711,16046,420Jul 16 05:47 PM
COZADD BRUCE CChairman & CEOJul 14Sale177.795,000888,950542,224Jul 16 05:47 PM
ENRIGHT PATRICK GDirectorJul 06Sale177.1110,0001,771,0555,696Jul 08 04:03 PM
Hooper Suzanne SawochkaEVP & General CounselJun 09Option Exercise46.834,000187,32050,420Jun 11 05:37 PM
Hooper Suzanne SawochkaEVP & General CounselJun 09Sale173.164,000692,64046,420Jun 11 05:37 PM
WILSON KAREN JSVP, Finance & PAOJun 02Sale180.0025746,26025,642Jun 03 06:34 PM
WILSON KAREN JSVP, Finance & PAOJun 01Option Exercise50.195,494275,73429,893Jun 03 06:34 PM
WILSON KAREN JSVP, Finance & PAOJun 01Sale179.575,494986,54825,899Jun 03 06:34 PM
ENRIGHT PATRICK GDirectorJun 01Sale178.7310,0001,787,3365,893Jun 03 04:04 PM
McGill IainSVP, Europe and Rest of WorldMay 26Option Exercise49.357,334361,90132,030May 28 07:11 PM
McGill IainSVP, Europe and Rest of WorldMay 26Sale179.487,3341,316,32624,696May 28 07:11 PM
O'Keefe Kenneth WDirectorMay 12Option Exercise46.834,500210,73510,650May 14 08:19 PM
Hooper Suzanne SawochkaEVP & General CounselMay 12Option Exercise46.832,07397,07950,297May 14 08:30 PM
COZADD BRUCE CChairman & CEOMay 12Sale173.855,000869,250551,967May 14 08:25 PM
O'Keefe Kenneth WDirectorMay 12Sale174.901,218213,0269,432May 14 08:19 PM
RIEDEL NORBERT GDirectorMay 12Sale173.86650113,0104,356May 14 08:12 PM
Gray PeterDirectorMay 12Sale173.86704122,4004,946May 14 07:58 PM
Hooper Suzanne SawochkaEVP & General CounselMay 12Sale173.854,000695,40046,297May 14 08:30 PM
ENRIGHT PATRICK GDirectorMay 11Sale176.1810,0001,761,7966,089May 13 04:01 PM
Cox Russell J.EVP & COOApr 14Sale181.4550090,72564,553Apr 16 08:10 PM
Hooper Suzanne SawochkaEVP & General CounselApr 14Sale181.454,000725,80048,224Apr 16 08:04 PM
COZADD BRUCE CChairman & CEOApr 14Sale181.455,000907,250556,967Apr 16 07:40 PM
ENRIGHT PATRICK GDirectorApr 06Sale169.1410,0001,691,4196,286Apr 08 04:05 PM
Mulligan SeamusDirectorMar 25Sale174.5950,0008,729,5221,157,205Mar 27 06:20 PM
Mulligan SeamusDirectorMar 18Sale185.0050,0009,250,0001,207,205Mar 20 08:22 PM
Hooper Suzanne SawochkaEVP & General CounselMar 10Option Exercise46.831,85186,68254,075Mar 12 08:27 PM
Hooper Suzanne SawochkaEVP & General CounselMar 10Sale170.361,851315,33652,224Mar 12 08:27 PM
COZADD BRUCE CChairman & CEOMar 10Sale170.355,000851,750561,967Mar 12 08:16 PM
Cox Russell J.EVP & COOMar 05Sale175.1050087,55065,053Mar 09 08:38 PM
WILSON KAREN JSVP, Finance & PAOMar 04Option Exercise28.035,159144,61026,205Mar 05 06:51 PM
WILSON KAREN JSVP, Finance & PAOMar 03Sale176.272,598457,94921,046Mar 05 06:51 PM
ENRIGHT PATRICK GDirectorMar 02Sale176.0010,0001,760,0316,482Mar 04 04:05 PM